Biologics, oral peptide and trivalent nanobody – current results and trends

Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from clinical trials and real-world settings for the currently approved monoclonal antibodies from the interleukin (IL)-23 and IL-17 inhibitor groups. In terms of personalized medicine, it is increasingly important to select a therapy option tailored to the respective conditions from the variety of treatment options.